CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

The iBiopsy® imaging biomarker discovery platform, which integrates advanced technologies in artificial intelligence has produced these results on one of the three indications on which it is positioned.

The ABRE Study is a prospective, interventional, single-arm, multi-center, worldwide study, which included 200 subjects with symptomatic iliofemoral venous outflow obstruction from 24 sites throughout the U.S. and Europe.

SAFER Sample Collection Kit is registered as a Class A medical device with the Health Sciences Authority of Singapore and is an easy-to-use saliva collection kit that comes with a bottle of stabilization fluid to be mixed with the sample at the point of collection, keeping viral RNA stable at room temperature for up to one week.

Omnipod 5 Automated Glucose Control System, Powered by Horizon™ (Omnipod 5), formerly known as the Omnipod Horizon System, is the first tubeless smartphone-controlled automated insulin delivery system for people living with diabetes.

Reflow Medical notes the OUS single-center clinical trial (NCT04162418) is expected to enroll up to 30 participants and last approximately six months.

Insulet expects to commercialize Omnipod, Powered by Horizon, in the U.S. in the first half of 2021, pending clearance by the FDA.

Hemovent reports the study concluded that Hemovent’s MOBYBOX ECLS device “provides excellent safety and physiologic efficacy in a 7-day (long-term) sheep experiment without visible clotting, hemolysis, or sustained reductions in fibrinogen or platelets.”

Total hip arthroplasty using a bearing combination of OXINIUM on XLPE versus traditional ceramic or metal constructs results in greatly improved survivorship and significantly reduced the need for revision. Read more.

The IMPACT study utilized the IBM Watson Truven Health Marketscan, a national commercial claims database, and analyzed data on 510 patients with lower limb amputations.